AUTHORS
Jessica Allen, MD, Yuxin Zhao Zhao, MS2, Xi Qiao, PhD3, Reid W Merryman, MD4, Sanjal Himanshu Desai, MBBS5, Robert Stuver, MD6, Azra Borogovac, MD7, Tiffany Chang8, Nivetha Ganesan, MPH9, Ellie Casper, MS, DPT10, Urshila Durani, MD, MPH11, Matthew Mei I, MD12, Alex Francisco Herrera, MD13, Alison Moskowitz, MD14, Kelsey Baron, MD15, Harsh Rohit Shah, DO16
AFFILIATIONS
1 Huntsman Cancer Institute, Salt Lake City, Utah, United States
2 Huntsman Cancer Institute, Salt Lake City, Utah, United States
3 Huntsman Cancer Institute, Salt Lake City, Utah, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Masonic Cancer Center, Minneapolis, Minnesota, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Huntsman Cancer Institute, Salt Lake City, Utah, United States
16 Huntsman Cancer Institute, Salt Lake City, Utah, United States
ABSTRACT
Introduction
The treatment paradigm for cHL shifted significantly with the integration of PD-1 monoclonal antibodies nivolumab and pembrolizumab into the frontline (1L) and R/R settings. With adoption of PD-1 across earlier lines of treatment (LOT), more patients (pts) require subsequent therapy after PD-1 exposure. Data on outcomes in this group, including the efficacy of PD-1 re-treatment, remain limited. We sought to evaluate the efficacy of PD-1 re-treatment in pts with R/R cHL.
Methods
This is a multicenter (6 US sites), retrospective study of pts ≥17 years (yr) with R/R cHL previously treated with PD-1, with first relapse on or after January 1 2022, and who were re-treatment with a PD-1-based regimen. Endpoints included overall response rate (ORR), complete response rate (CRR), progression-free survival (PFS), and overall survival (OS).? PFS was defined as the time from second PD-1 treatment to relapse or death from any cause.? Univariable Cox proportional hazards regression analyses were conducted on complete cases to evaluate associations between baseline/treatment characteristics and survival after second PD-1 treatment.
Results
Out of 139 pts with PD-1 re-treatment, median age at initial diagnosis was 35 yrs (range 17-87), 45% (n=62) were male, and 74% (n=90) were White. Most pts (52%, n=67) had stage III/IV disease, and 52% (n=71) had primary refractory disease. Median LOT of first PD-1 exposure was 3rd line (L) (range 1-11; n=21 1L, n=39 2L, n=23 3L, n=28 4L, n=25 5L+). Regimens at 1st PD-1 exposure were PD-1 monotherapy (n=66, 47%), PD-1 with chemotherapy (chemo) (n=44, 32%), PD-1 with other (hypomethylating agents, histone deacetylase inhibitors, or ruxolitinib, [n=16, 12%]), and PD-1 with brentuximab vedotin (BV) (n=13, 9%). In 124 pts with available best response to first PD-1, CRR was 32% and ORR was 82%. Thirty percent (n=42) of pts had first PD-1 exposure after autologous stem cell transplant (autoSCT).
Median LOT of second PD-1 exposure was 5L (range 2-17; n=18 2L, n=30 3L, n=21 4L, n=28 5L, n=15 6L, n=27 7L+). Regimens at PD-1 re-treatment included 37% (n=51) PD-1 monotherapy, 27% (n=38) PD-1 with chemo, 18% (n=25) PD-1 with BV, and 18% (n=25) PD-1 with other. At PD-1 re-treatment, 37% (n=51) of pts were re-treated with the same partner regimen (n=28 PD-1 monotherapy, n=22 PD-1 with chemo, n=1 PD-1 with BV). Of 74 patients with complete data for timing between PD-1 re-treatment, 26% were re-challenged within 3 months, 12% from 3-6 months, 26% from 6-12 months, and 36% after 12 months. Between initial PD-1 exposures, 65 pts had an intervening therapy (autoSCT n=55 (40%); allogeneic SCT n=11 (8%).
In 118 response-evaluable pts, the ORR was 76% and the CRR was 51% after PD-1 re-treatment. There were no differences in response rates in pts re-treated with the same PD-1 partner regimen and those re-treated with a different regimen (ORR p=0.6, CRR p=0.3). Response rates were significantly different when second PD-1 partner regimens were compared, with significantly lower ORR and CRR, respectively, in pts who received PD-1 monotherapy (59%, 37%) and PD-1 plus other agent (62%, 24%) compared with PD-1 with chemo (97%, 85%) and PD-1 with BV (91%, 50%) (p=<0.001 for ORR and CRR).
At a median follow-up of 1.8 yrs from PD-1 re-treatment, the median PFS and OS were not reached. The estimated 1-yr PFS was 82% (95%CI 76-89%) and 1-yr OS was 96% (95%CI 92-100%).
In univariable analysis, receipt of autoSCT before PD-1 re-treatment was significantly associated with lower risk of progression or death (HR 0.2, 95%CI 0.1-0.6). No significant associations with PFS after PD-1 re-treatment were observed for best response to first PD-1 (CR vs PR vs SD vs PD), PD-1 partner regimen at first or second exposure, re-treatment with same PD-1 partner regimen, and time between PD-1 exposures (<3 months, 3-6 months, 6-12 months, > 12 months).
Conclusions
In this real-world cohort, PD-1 re-treatment demonstrated robust 1-yr survival and high response rates in R/R cHL. Combining PD-1 with chemo or BV at re-treatment yielded significantly superior response rates compared to PD-1 monotherapy and PD-1 with other. The best response to initial PD-1 exposure and the timing between PD-1 re-treatment in our limited number of patients did not significantly impact survival after PD-1 re-treatment. Further data is needed on optimal timing between PD-1 exposures and optimal treatment sequencing.
DISCLOSURES
Jessica Allen, MD: No relevant conflicts of interest to declare.